# A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

> **NCT07100106** · PHASE1,PHASE2 · RECRUITING · sponsor: **Genentech, Inc.** · enrollment: 285 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** GDC-4198
- **DRUG:** Giredestrant
- **DRUG:** Abemaciclib

## Key facts

- **NCT ID:** NCT07100106
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-07
- **Primary completion:** 2028-08-31
- **Final completion:** 2028-08-31
- **Target enrollment:** 285 (ESTIMATED)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07100106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07100106, "A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT07100106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*